期刊文献+

缩血管物质与门脉高压症的研究进展 被引量:2

Progress of vasoconstrictors and portal hypertension
原文传递
导出
摘要 目的总结研究缩血管物质和门脉高压症之间关系的观点。方法收集近年来报道血管紧张素Ⅱ和内皮素与门脉高压症之间关系的文章进行分析总结。结果血管紧张素Ⅱ和内皮素通过肝星状细胞作用影响肝纤维化和门静脉压力。结论血管紧张素Ⅱ和内皮素在门脉高压症的发病中起重要作甩;血管紧张素Ⅱ拮抗剂和内皮素拮抗剂能有效降低门静脉压力,进而改善肝纤维化。 Objective We summarized the views between vasoconstrictors and portal hypertension. Methods Many articles of the Angiotensin Ⅱ and endothelin were revi.ewed. Results The Angiotensin Ⅱ and endothelin influence portal venous pressure, haemodynamics and hepatic fibrosis through the HSC. Conclusions The Angiotensin Ⅱ and endothelin are involved in the pathogenesis of cirrhosis and portal hypertension. The Angiotensin Ⅱ and endothelin receptor antagonist can effectively improve hepatic haemodynamics, accordingly reduce the portal venous pressure in cirrhosis.
出处 《国际外科学杂志》 2008年第2期114-117,共4页 International Journal of Surgery
关键词 缩血管物质 门脉高压症 血管紧张素Ⅱ 内皮素 vasoconstrictors portal hypertension
  • 相关文献

参考文献3

二级参考文献27

  • 1Feng Liu1,Ji Xin Li2, Chun Mei Li2,Xi Sheng Leng2 1Department of General Surgery, the Fifth Affiliated Hospital, Harbin Medical University, Harbin 150036, Heilongjiang Province, China2Department of General Surgery, People’s Hospital, Medical University, Beijing 100044, China.Plasma endothelin in patients with endotoxemia and dynamic comparison between vasoconstrictor and vasodilator in cirrhotic patients[J].World Journal of Gastroenterology,2001,7(1):126-127. 被引量:8
  • 2Guo Liang Zhang Ye Hong Wang Hui Ling Teng Zhi Bin Lin Department of Pharmacology,School of Basic Medical Sciences,Beijing University,Beijiog 100083,ChinaDr.Guo Liang Zhang graduated from Xinxiang Medical College in 1982,got Ph.D.at Nagoya City University Medical School,Japan in 1994,finished postdoctoral research at Beijing Medical Univcrsity in 1996,now an associate professor of pharmacology,specialized in hepatic pharmacology,having 15 papers published..Effects of aminoguanidine on nitric oxide production induced by inflammatory cytokines and endotoxin in cultured rat hepatocytes[J].World Journal of Gastroenterology,2001,7(3):331-334. 被引量:20
  • 3Groszmann RJ, Abraldes JG. Portal hypertension, from bedside to bench. J Clin Gastroenterol, 2005, 39 : S125-S130. 被引量:1
  • 4Colle I, De Vriese AS, Van Vlierberghe H, et al. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int,2004, 24( 1 ) : 63-68. 被引量:1
  • 5Theodorakis NG, Wang YN, Skill N J, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in geneknockout mice, Gastroenterology, 2003, 124 ( 5 ) : 1500-1508. 被引量:1
  • 6Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology, 2003, 125:1452-1461. 被引量:1
  • 7Iwakiri Y, Tsai MH, McCabe TJ, et al. Phospborylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol, 2002, 282 (6) : H2084-H2090. 被引量:1
  • 8Gadano AC, Sogni P, Heller J, et al. Vascular nitric oxide production during the development of two experimental models of portal hypertension. J Hepatol, 1999, 30(5): 896-903. 被引量:1
  • 9Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med, 2003, 139(3):186-193. 被引量:1
  • 10Biecker E, Sagesser H, Reichen J. Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice. Eur J Clin Invest, 2004, 34(4): 283-289. 被引量:1

共引文献74

同被引文献31

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部